首页 > 最新文献

BMJ Sexual & Reproductive Health最新文献

英文 中文
Scaling postpartum family planning services in the Democratic Republic of Congo: outcomes and lessons learned. 在刚果民主共和国推广产后计划生育服务:成果与经验教训。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-11 DOI: 10.1136/bmjsrh-2023-202114
Rita Kabra, Komal Preet Allagh, Brigitte Nsiku Kini, Robert Mulunda Kanke, James Kiarie
{"title":"Scaling postpartum family planning services in the Democratic Republic of Congo: outcomes and lessons learned.","authors":"Rita Kabra, Komal Preet Allagh, Brigitte Nsiku Kini, Robert Mulunda Kanke, James Kiarie","doi":"10.1136/bmjsrh-2023-202114","DOIUrl":"10.1136/bmjsrh-2023-202114","url":null,"abstract":"","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11041570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient and public involvement in abortion research: reflections from the Shaping Abortion for Change (SACHA) Study. 堕胎研究中的患者和公众参与:塑造堕胎促进变革(SACHA)研究的反思。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-11 DOI: 10.1136/bmjsrh-2023-202018
Rebecca Blaylock, Maria Lewandowska, Charlotte Kelly, Becky Gunn, Rebecca Meiksin, Rachel H Scott, Melissa J Palmer, Kaye Wellings, Patricia A Lohr, Rebecca S French, The Sacha Study Team N/A

Patient and public involvement (PPI) is limited within abortion-related research. Possible reasons for this include concerns about engaging with a stigmatised patient group who value confidentiality and may be reluctant to re-engage with services. Structural barriers, including limited funding for abortion-related research, also prevent researchers from creating meaningful PPI opportunities. Here, we describe lessons learnt on undertaking PPI as part of the Shaping Abortion for Change (SACHA) Study, which sought to create an evidence base to guide new directions in abortion care in Britain.Two approaches to PPI were used: involving patients and the public in the oversight of the research and its dissemination as lay advisors, and group meetings to obtain patients' views on interpretation of findings and recommendations. All participants observed the SACHA findings aligned with their own experiences of having an abortion in Britain. These priorities aligned closely with those identified in a separate expert stakeholder consultation undertaken as part of the SACHA Study. One additional priority which had not been identified during the research was identified by the PPI participants.We found abortion patients to be highly motivated to engage in the group meetings, and participation in them actively contributed to the destigmatisation of abortion by giving them a space to share their experiences. This may alleviate any ethical concerns about conducting research and PPI on abortion, including the assumption that revisiting an abortion experience will cause distress. We hope that our reflections are useful to others considering PPI in abortion-related research and service improvement.

在堕胎相关研究中,患者和公众参与 (PPI) 有限。可能的原因包括,研究人员担心与被污名化的患者群体接触,他们重视保密性,可能不愿意重新接受服务。结构性障碍,包括人工流产相关研究的资金有限,也阻碍了研究人员创造有意义的 PPI 机会。在此,我们介绍了作为 "塑造堕胎变革(SACHA)研究 "一部分的 "公众参与"(PPI)的经验教训,该研究旨在创建一个证据基础,以指导英国堕胎护理的新方向。"公众参与 "采用了两种方法:让患者和公众作为非专业顾问参与研究的监督和传播,以及召开小组会议以了解患者对研究结果和建议的解释。所有参与者都认为 SACHA 的研究结果与他们在英国堕胎的亲身经历相吻合。这些优先事项与作为 SACHA 研究一部分的单独专家利益相关者咨询中确定的优先事项非常一致。我们发现人工流产患者参与小组会议的积极性很高,参与小组会议为他们提供了一个分享经验的空间,从而积极促进了人工流产的去污名化。这可能会减轻人们对开展流产研究和 PPI 的伦理顾虑,包括重温流产经历会造成痛苦的假设。我们希望我们的思考对其他考虑在人工流产相关研究和服务改进中开展 PPI 的人有所帮助。
{"title":"Patient and public involvement in abortion research: reflections from the Shaping Abortion for Change (SACHA) Study.","authors":"Rebecca Blaylock, Maria Lewandowska, Charlotte Kelly, Becky Gunn, Rebecca Meiksin, Rachel H Scott, Melissa J Palmer, Kaye Wellings, Patricia A Lohr, Rebecca S French, The Sacha Study Team N/A","doi":"10.1136/bmjsrh-2023-202018","DOIUrl":"10.1136/bmjsrh-2023-202018","url":null,"abstract":"<p><p>Patient and public involvement (PPI) is limited within abortion-related research. Possible reasons for this include concerns about engaging with a stigmatised patient group who value confidentiality and may be reluctant to re-engage with services. Structural barriers, including limited funding for abortion-related research, also prevent researchers from creating meaningful PPI opportunities. Here, we describe lessons learnt on undertaking PPI as part of the Shaping Abortion for Change (SACHA) Study, which sought to create an evidence base to guide new directions in abortion care in Britain.Two approaches to PPI were used: involving patients and the public in the oversight of the research and its dissemination as lay advisors, and group meetings to obtain patients' views on interpretation of findings and recommendations. All participants observed the SACHA findings aligned with their own experiences of having an abortion in Britain. These priorities aligned closely with those identified in a separate expert stakeholder consultation undertaken as part of the SACHA Study. One additional priority which had not been identified during the research was identified by the PPI participants.We found abortion patients to be highly motivated to engage in the group meetings, and participation in them actively contributed to the destigmatisation of abortion by giving them a space to share their experiences. This may alleviate any ethical concerns about conducting research and PPI on abortion, including the assumption that revisiting an abortion experience will cause distress. We hope that our reflections are useful to others considering PPI in abortion-related research and service improvement.</p>","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11041545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139711519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opt-in versus universal codeine provision for medical abortion up to 10 weeks of gestation at British Pregnancy Advisory Service: a cross-sectional evaluation. 英国妊娠咨询服务机构为妊娠 10 周以内的药物流产提供可待因的选择性与普遍性:横断面评估。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-11 DOI: 10.1136/bmjsrh-2023-201893
Neda Taghinejadi, Hannah McCulloch, Michał Krassowski, Amelia McInnes-Dean, Katherine C Whitehouse, Patricia A Lohr

Objective: To assess patient experiences of pain management during medical abortion up to 10 weeks' gestation with opt-in versus universal codeine provision.

Methods: We invited patients who underwent medical abortion up to 10 weeks of gestation to participate in an online, anonymous, English-language survey from November 2021 to March 2022. We performed ordinal regression analyses to compare satisfaction with pain management (5-point Likert scale) and maximum abortion pain score (11-point numerical rating scale) in the opt-in versus universal codeine provision groups.

Results: Of 11 906 patients invited to participate, 1625 (13.6%) completed the survey. Participants reported a mean maximum pain score of 6.8±2.2. A total of 1149 participants (70.7%) reported using codeine for pain management during their abortion. Participants in the opt-in codeine provision group were significantly more likely to be satisfied with their pain management than those in the universal group (aOR 1.48, 95% CI 1.12 to 1.96, p<0.01). Maximum abortion pain scores were lower on average among the opt-in codeine provision group (OR 0.80, 95% CI 0.66 to 0.96, p=0.02); however, this association was not statistically significant in the model adjusted for covariates (aOR 0.85, 95% CI 0.70 to 1.03, p=0.09).

Conclusion: Our findings suggest that patients have a better experience with pain management during medical abortion when able to opt-in to codeine provision following counselling versus receiving this medication routinely.

目的评估患者在妊娠 10 周以内药物流产过程中选择提供可待因还是普遍提供可待因的疼痛管理经验:我们邀请妊娠 10 周以内接受药物流产的患者参与 2021 年 11 月至 2022 年 3 月期间的匿名在线英语调查。我们进行了序数回归分析,比较了选择提供可待因组和普遍提供可待因组的疼痛管理满意度(5 点李克特量表)和最大流产疼痛评分(11 点数字评分量表):在受邀参与调查的 11 906 名患者中,1625 人(13.6%)完成了调查。参与者报告的平均最大疼痛评分为 6.8±2.2。共有 1149 名参与者(70.7%)表示在流产过程中使用了可待因止痛。选择提供可待因组的参与者对疼痛控制满意度明显高于普通组(aOR 1.48,95% CI 1.12 至 1.96,pConclusion):我们的研究结果表明,与常规接受可待因药物治疗相比,如果患者能够在咨询后选择接受可待因药物治疗,他们在药物流产过程中的疼痛治疗体验会更好。
{"title":"Opt-in versus universal codeine provision for medical abortion up to 10 weeks of gestation at British Pregnancy Advisory Service: a cross-sectional evaluation.","authors":"Neda Taghinejadi, Hannah McCulloch, Michał Krassowski, Amelia McInnes-Dean, Katherine C Whitehouse, Patricia A Lohr","doi":"10.1136/bmjsrh-2023-201893","DOIUrl":"10.1136/bmjsrh-2023-201893","url":null,"abstract":"<p><strong>Objective: </strong>To assess patient experiences of pain management during medical abortion up to 10 weeks' gestation with opt-in versus universal codeine provision.</p><p><strong>Methods: </strong>We invited patients who underwent medical abortion up to 10 weeks of gestation to participate in an online, anonymous, English-language survey from November 2021 to March 2022. We performed ordinal regression analyses to compare satisfaction with pain management (5-point Likert scale) and maximum abortion pain score (11-point numerical rating scale) in the opt-in versus universal codeine provision groups.</p><p><strong>Results: </strong>Of 11 906 patients invited to participate, 1625 (13.6%) completed the survey. Participants reported a mean maximum pain score of 6.8±2.2. A total of 1149 participants (70.7%) reported using codeine for pain management during their abortion. Participants in the opt-in codeine provision group were significantly more likely to be satisfied with their pain management than those in the universal group (aOR 1.48, 95% CI 1.12 to 1.96, p<0.01). Maximum abortion pain scores were lower on average among the opt-in codeine provision group (OR 0.80, 95% CI 0.66 to 0.96, p=0.02); however, this association was not statistically significant in the model adjusted for covariates (aOR 0.85, 95% CI 0.70 to 1.03, p=0.09).</p><p><strong>Conclusion: </strong>Our findings suggest that patients have a better experience with pain management during medical abortion when able to opt-in to codeine provision following counselling versus receiving this medication routinely.</p>","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139721634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Women's experiences of postpartum contraceptive services when elective caesarean section is the method of birth: a qualitative study. 选择剖腹产作为分娩方式的妇女对产后避孕服务的体验:一项定性研究。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-11 DOI: 10.1136/bmjsrh-2023-202046
Karin Lichtenstein Liljeblad, Helena Kopp Kallner, Jan Brynhildsen, Helena Kilander

Background: The unmet need for postpartum contraception is a global challenge. Postpartum placement of an intrauterine device (IUD) within 48 hours of vaginal delivery is available in many settings worldwide, but is not routinely practised in Sweden. To improve contraceptive services and facilitate the informed choice of IUD placement at the time of a caesarean section (CS), we performed this study to identify and describe women's experiences of contraceptive services before, during and after an elective CS.

Methods: A qualitative design and methodology was used. We interviewed 20 women aged 28-42 years who underwent elective CS in Sweden. Interviews were analysed using reflexive thematic analysis.

Results: The three main themes found were (1) receptivity to contraceptive counselling in the context of CS, (2) communication and decision-making about postpartum contraception before CS and (3) lack of support and guidance to receive contraceptive services before and after CS. The participants described readiness and interest regarding postpartum contraception. They prefered counselling from around 25 weeks of gestation. Despite this finding, antenatal communication and contraceptive decision-making seemed rare. Participants reported a lack of support and guidance which necessitated a need by women to navigate the contraceptive services themselves in order to receive information about contraception before CS and to receive postpartum support.

Conclusions: Antenatal contraceptive counselling including information about IUD placement during CS was appreciated and welcomed by women with elective CS as their birth method. Most of the women whom we interviewed would prefer to receive contraception counselling on postpartum use during the second half of their pregnancy.

背景:产后避孕需求得不到满足是一项全球性挑战。产后在阴道分娩后 48 小时内放置宫内节育器(IUD)在全球许多地方都可实现,但在瑞典尚未常规实施。为了改善避孕服务并促进在剖腹产(CS)时在知情的情况下选择放置宫内节育器,我们开展了这项研究,以确定并描述妇女在选择性剖腹产之前、期间和之后对避孕服务的体验:研究采用了定性设计和方法。我们采访了 20 名在瑞典接受选择性 CS 的 28-42 岁女性。采用反思性主题分析法对访谈进行分析:发现的三大主题是:(1)在 CS 的背景下接受避孕咨询;(2)CS 前关于产后避孕的沟通和决策;(3)CS 前后在接受避孕服务方面缺乏支持和指导。参与者描述了对产后避孕的准备情况和兴趣。他们倾向于在妊娠 25 周左右开始接受咨询。尽管如此,产前沟通和避孕决策似乎并不多见。参与者报告称,由于缺乏支持和指导,妇女需要自己掌握避孕服务,以便在分娩前获得避孕信息,并在产后获得支持:结论:产前避孕咨询,包括在 CS 期间放置宫内节育器的相关信息,受到了选择 CS 作为生育方法的妇女的赞赏和欢迎。我们采访的大多数妇女都希望在妊娠后半期接受有关产后使用避孕药具的咨询。
{"title":"Women's experiences of postpartum contraceptive services when elective caesarean section is the method of birth: a qualitative study.","authors":"Karin Lichtenstein Liljeblad, Helena Kopp Kallner, Jan Brynhildsen, Helena Kilander","doi":"10.1136/bmjsrh-2023-202046","DOIUrl":"10.1136/bmjsrh-2023-202046","url":null,"abstract":"<p><strong>Background: </strong>The unmet need for postpartum contraception is a global challenge. Postpartum placement of an intrauterine device (IUD) within 48 hours of vaginal delivery is available in many settings worldwide, but is not routinely practised in Sweden. To improve contraceptive services and facilitate the informed choice of IUD placement at the time of a caesarean section (CS), we performed this study to identify and describe women's experiences of contraceptive services before, during and after an elective CS.</p><p><strong>Methods: </strong>A qualitative design and methodology was used. We interviewed 20 women aged 28-42 years who underwent elective CS in Sweden. Interviews were analysed using reflexive thematic analysis.</p><p><strong>Results: </strong>The three main themes found were (1) receptivity to contraceptive counselling in the context of CS, (2) communication and decision-making about postpartum contraception before CS and (3) lack of support and guidance to receive contraceptive services before and after CS. The participants described readiness and interest regarding postpartum contraception. They prefered counselling from around 25 weeks of gestation. Despite this finding, antenatal communication and contraceptive decision-making seemed rare. Participants reported a lack of support and guidance which necessitated a need by women to navigate the contraceptive services themselves in order to receive information about contraception before CS and to receive postpartum support.</p><p><strong>Conclusions: </strong>Antenatal contraceptive counselling including information about IUD placement during CS was appreciated and welcomed by women with elective CS as their birth method. Most of the women whom we interviewed would prefer to receive contraception counselling on postpartum use during the second half of their pregnancy.</p>","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11041589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139746147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contraception prescribing in England during the COVID-19 pandemic. 新冠肺炎大流行期间英格兰的避孕处方。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-11 DOI: 10.1136/bmjsrh-2023-201856
Tanha Begum, Emer Cullen, Malcolm Moffat, Judith Rankin

Background: National lockdowns in England due to COVID-19 resulted in rapid shifts in healthcare provision, including in primary care where most contraceptive prescriptions are issued. This study aimed to investigate contraception prescribing trends in primary care during the pandemic and the impact of socioeconomic deprivation.

Methods: Prescribing data were accessed from the English Prescribing Dataset for the first year of the COVID-19 pandemic (1 March 2020-28 February 2021) and the year prior (1 March 2019-29 February 2020). Data were analysed by geographical region (London, Midlands and East of England, North of England, South of England) and contraceptive type (progestogen-only pill (POP), combined oral contraception (COC), emergency hormonal contraception (EHC) and contraceptive injections). Differences in prescribing rates were calculated using Poisson regression. Pearson correlation coefficients were calculated for the Index of Multiple Deprivation (IMD) scores for each Clinical Commissioning Group (CCG) in the North East and North Cumbria (NENC).

Results: Contraception prescribing rates decreased overall during the COVID-19 pandemic in England (Poisson regression coefficient (β)=-0.035), with a statistically significant (p<0.01) decrease in all four regions. Prescriptions decreased for COC (β=-0.978), contraceptive injections (β=-0.161) and EHC (β=-0.2005), while POP (β=0.050) prescribing rates increased. There was a weak positive correlation between IMD and prescribing rates in NENC (p>0.05).

Conclusions: Contraception provision was impacted by COVID-19 with an overall decrease in prescribing rates. The deprivation results suggest that this may not be a significant contributing factor to this decrease. Further research is recommended to better understand these changes, and to ensure that services respond appropriately to population needs.

背景:新冠肺炎导致英格兰全国封锁,导致医疗服务的迅速转变,包括初级保健,大多数避孕处方都是在初级保健中开具的。这项研究旨在调查疫情期间初级保健中的避孕处方趋势以及社会经济剥夺的影响。方法:从新冠肺炎大流行第一年(2020-28年3月1日至2021年2月8日)和前一年(2019-29年3月9日)的英国处方数据集中获取处方数据。数据按地理区域(伦敦、英格兰中部和东部、英格兰北部、英格兰南部)和避孕类型(仅含孕激素的药丸(POP)、联合口服避孕(COC)、紧急激素避孕(EHC)和避孕注射)进行分析。使用泊松回归计算处方率的差异。计算东北部和北坎布里亚郡(NENC)每个临床调试组(CCG)的多重剥夺指数(IMD)分数的Pearson相关系数。结果:在新冠肺炎大流行期间,英国避孕处方率总体下降(泊松回归系数(β)=-0.035),具有统计学意义(p0.05)。剥夺的结果表明,这可能不是导致这种减少的重要因素。建议进行进一步的研究,以更好地了解这些变化,并确保服务适当地满足人口需求。
{"title":"Contraception prescribing in England during the COVID-19 pandemic.","authors":"Tanha Begum, Emer Cullen, Malcolm Moffat, Judith Rankin","doi":"10.1136/bmjsrh-2023-201856","DOIUrl":"10.1136/bmjsrh-2023-201856","url":null,"abstract":"<p><strong>Background: </strong>National lockdowns in England due to COVID-19 resulted in rapid shifts in healthcare provision, including in primary care where most contraceptive prescriptions are issued. This study aimed to investigate contraception prescribing trends in primary care during the pandemic and the impact of socioeconomic deprivation.</p><p><strong>Methods: </strong>Prescribing data were accessed from the English Prescribing Dataset for the first year of the COVID-19 pandemic (1 March 2020-28 February 2021) and the year prior (1 March 2019-29 February 2020). Data were analysed by geographical region (London, Midlands and East of England, North of England, South of England) and contraceptive type (progestogen-only pill (POP), combined oral contraception (COC), emergency hormonal contraception (EHC) and contraceptive injections). Differences in prescribing rates were calculated using Poisson regression. Pearson correlation coefficients were calculated for the Index of Multiple Deprivation (IMD) scores for each Clinical Commissioning Group (CCG) in the North East and North Cumbria (NENC).</p><p><strong>Results: </strong>Contraception prescribing rates decreased overall during the COVID-19 pandemic in England (Poisson regression coefficient (β)=-0.035), with a statistically significant (p<0.01) decrease in all four regions. Prescriptions decreased for COC (β=-0.978), contraceptive injections (β=-0.161) and EHC (β=-0.2005), while POP (β=0.050) prescribing rates increased. There was a weak positive correlation between IMD and prescribing rates in NENC (p>0.05).</p><p><strong>Conclusions: </strong>Contraception provision was impacted by COVID-19 with an overall decrease in prescribing rates. The deprivation results suggest that this may not be a significant contributing factor to this decrease. Further research is recommended to better understand these changes, and to ensure that services respond appropriately to population needs.</p>","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49674452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors affecting female sexual well-being: a 5-year follow-up of a randomised clinical trial on post-abortion contraception. 影响女性性健康的因素:一项关于堕胎后避孕的随机临床试验的5年随访。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-11 DOI: 10.1136/bmjsrh-2023-201879
Janina Bosas, Elena Toffol, Elina Pohjoranta, Maarit J Mentula, Ritva Hurskainen, Satu Suhonen, Oskari Heikinheimo

Introduction: Sexual well-being is associated with general well-being. Several factors, such as overweight, infertility, anxiety and sex hormones, also play a role, but the effects of hormonal contraception remain a point of debate. We characterised the factors associated with sexual well-being in fertile-aged women following induced abortion.

Methods: A 5-year follow-up of a nested, longitudinal, cohort study examining the effects of routine provision of intrauterine contraception as part of abortion care. Sexual well-being, anxiety and quality of life were assessed annually using validated questionnaires (McCoy Female Sexuality Questionnaire, State-Trait Anxiety Inventory and EuroQoL), along with data on general and reproductive health, and relationship status. Of the 742 women participating in the trial, 290 (39%) provided sufficient follow-up data and were included in this study.

Results: Based on trajectories of McCoy scores across the 5-year follow-up, two groups were identified: those with stable and higher (n=223, 76.9%) and those with declining sexual well-being (n=67, 23.1%). Women in the group of declining sexual well-being had significantly higher levels of anxiety and lower quality of life at all time points. They also had chronic diseases more often and were less happy in their relationships. No differences were found in method of contraception when classified as hormonal versus non-hormonal, or long-acting versus short-acting reversible contraception.

Conclusions: Lower anxiety and higher quality of life are associated with stable and higher sexual well-being. Method of contraception or relationship status are not associated with sexual well-being during long-term follow-up in fertile-aged women.

引言:性幸福感与总体幸福感有关。超重、不孕、焦虑和性激素等几个因素也起到了一定作用,但激素避孕的效果仍然是一个争论点。我们描述了人工流产后育龄老年妇女性健康的相关因素。方法:对一项嵌套、纵向、队列研究进行5年随访,研究常规提供宫内避孕作为堕胎护理的一部分的效果。每年使用经验证的问卷(McCoy女性性行为问卷、状态特质焦虑量表和EuroQoL),以及一般和生殖健康以及关系状况的数据,对性健康、焦虑和生活质量进行评估。742 参与试验的290名女性(39%)提供了足够的随访数据,并被纳入本研究。结果:根据5年随访中McCoy评分的轨迹,确定了两组:性健康状况稳定且较高的组(n=223,76.9%)和性健康状况下降的组(n=67,23.1%)。性健康状况恶化组中的女性在所有时间点的焦虑水平均显著较高,生活质量较低。他们还经常患有慢性病,在恋爱关系中也不那么快乐。当分类为激素与非激素,或长效与短效可逆避孕时,在避孕方法上没有发现差异。结论:较低的焦虑和较高的生活质量与稳定和较高的性幸福感有关。在育龄妇女的长期随访中,避孕方法或关系状况与性健康无关。
{"title":"Factors affecting female sexual well-being: a 5-year follow-up of a randomised clinical trial on post-abortion contraception.","authors":"Janina Bosas, Elena Toffol, Elina Pohjoranta, Maarit J Mentula, Ritva Hurskainen, Satu Suhonen, Oskari Heikinheimo","doi":"10.1136/bmjsrh-2023-201879","DOIUrl":"10.1136/bmjsrh-2023-201879","url":null,"abstract":"<p><strong>Introduction: </strong>Sexual well-being is associated with general well-being. Several factors, such as overweight, infertility, anxiety and sex hormones, also play a role, but the effects of hormonal contraception remain a point of debate. We characterised the factors associated with sexual well-being in fertile-aged women following induced abortion.</p><p><strong>Methods: </strong>A 5-year follow-up of a nested, longitudinal, cohort study examining the effects of routine provision of intrauterine contraception as part of abortion care. Sexual well-being, anxiety and quality of life were assessed annually using validated questionnaires (McCoy Female Sexuality Questionnaire, State-Trait Anxiety Inventory and EuroQoL), along with data on general and reproductive health, and relationship status. Of the 742 women participating in the trial, 290 (39%) provided sufficient follow-up data and were included in this study.</p><p><strong>Results: </strong>Based on trajectories of McCoy scores across the 5-year follow-up, two groups were identified: those with stable and higher (n=223, 76.9%) and those with declining sexual well-being (n=67, 23.1%). Women in the group of declining sexual well-being had significantly higher levels of anxiety and lower quality of life at all time points. They also had chronic diseases more often and were less happy in their relationships. No differences were found in method of contraception when classified as hormonal versus non-hormonal, or long-acting versus short-acting reversible contraception.</p><p><strong>Conclusions: </strong>Lower anxiety and higher quality of life are associated with stable and higher sexual well-being. Method of contraception or relationship status are not associated with sexual well-being during long-term follow-up in fertile-aged women.</p>","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49674453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual and reproductive health clinical consultations: domestic abuse. 性与生殖健康临床咨询:家庭虐待。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-11 DOI: 10.1136/bmjsrh-2023-201993
Melissa Gardner, Jayne Kavanagh
{"title":"Sexual and reproductive health clinical consultations: domestic abuse.","authors":"Melissa Gardner, Jayne Kavanagh","doi":"10.1136/bmjsrh-2023-201993","DOIUrl":"10.1136/bmjsrh-2023-201993","url":null,"abstract":"","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing an accessible audiovisual animation to provide information about postpartum contraception. 制作无障碍视听动画,提供有关产后避孕的信息。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-08 DOI: 10.1136/bmjsrh-2023-202050
M. Cooper, Hannah Robinson, Leanne Hughes, Karen McCabe, Janine Simpson, Sharon Cameron
{"title":"Developing an accessible audiovisual animation to provide information about postpartum contraception.","authors":"M. Cooper, Hannah Robinson, Leanne Hughes, Karen McCabe, Janine Simpson, Sharon Cameron","doi":"10.1136/bmjsrh-2023-202050","DOIUrl":"https://doi.org/10.1136/bmjsrh-2023-202050","url":null,"abstract":"","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140732445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is new in breast cancer and contraception? A statement from the Faculty of Sexual & Reproductive Healthcare (FSRH). 乳腺癌与避孕的新进展?性与生殖保健学院(FSRH)的声明。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-03 DOI: 10.1136/bmjsrh-2024-202304
Ellen Adams, Katie Boog, Sarah Margaret Hardman
{"title":"What is new in breast cancer and contraception? A statement from the Faculty of Sexual & Reproductive Healthcare (FSRH).","authors":"Ellen Adams, Katie Boog, Sarah Margaret Hardman","doi":"10.1136/bmjsrh-2024-202304","DOIUrl":"https://doi.org/10.1136/bmjsrh-2024-202304","url":null,"abstract":"","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140746757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Japan initiates a groundbreaking market test of over-the-counter emergency contraceptive pills with pharmacies as a first access point. 日本对非处方药紧急避孕药进行了开创性的市场测试,将药店作为第一接入点。
IF 3.3 3区 医学 Q2 Medicine Pub Date : 2024-04-03 DOI: 10.1136/bmjsrh-2024-202221
Hayase Hakariya, Takanao Hashimoto, Yosuke Suzuki, Tamae Hamaki, Tetsuya Tanimoto
{"title":"Japan initiates a groundbreaking market test of over-the-counter emergency contraceptive pills with pharmacies as a first access point.","authors":"Hayase Hakariya, Takanao Hashimoto, Yosuke Suzuki, Tamae Hamaki, Tetsuya Tanimoto","doi":"10.1136/bmjsrh-2024-202221","DOIUrl":"https://doi.org/10.1136/bmjsrh-2024-202221","url":null,"abstract":"","PeriodicalId":9219,"journal":{"name":"BMJ Sexual & Reproductive Health","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140749152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMJ Sexual & Reproductive Health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1